Estée Lauder Splits K-Beauty: Dr.Jart+ Now Sold Separately

Estée Lauder Companies has reached the final stage of a process to divest three legacy assets, with Korean clinical skincare brand Dr.Jart+ now being marketed to potential acquirers separately from the makeup labels Too Faced and Smashbox, according to reporting from WWD and Business of Fashion. The decision, disclosed May 15, places the K-beauty brand back on the market roughly six years after Estée Lauder paid approximately $1.7 billion for control of parent company Have & Be Co. The combined price for the three-brand package is estimated in the low nine figures. ## A Six-Year K-Beauty Bet, Unwound When Estée Lauder closed its acquisition of Have & Be Co. in December 2019, the deal was the company's first majority purchase of an Asia-based beauty brand and one of the largest K-beauty transactions on record. Estée Lauder bought roughly two-thirds of Have & Be for about $1.1 billion, valuing the parent at $1.7 billion, and projected that Dr.Jart+ would clear $500 million in net sales for that calendar year, according to the company's [SEC filing](https://www.sec.gov/Archives/edgar/data/1001250/000110465919064930/tm1920881d4_ex99-1.htm){rel="nofollow noopener" target="_blank"}. The strategic logic was specific. Dr.Jart+ had been founded in 2004 by dermatologist Jung Sung-jae and entrepreneur Lee Chin-wook, who built the brand on a dermatologist-led positioning before launching the first BB cream to enter mass U.S. retail. By 2019, the brand's Cicapair Tiger Grass line (centered on Centella asiatica) and Ceramidin barrier line had given Estée Lauder a credible clinical-skincare asset built around two of the most-studied actives in modern barrier repair: the [pentacyclic triterpenes in Centella asiatica](/science/centella-asiatica-cica-skincare-science/) and the [skin-identical ceramides](/science/ceramide-types-skin-barrier-function/) that anchor the stratum corneum. Acquiring Dr.Jart+ gave Estée Lauder a foothold in K-beauty without disturbing the positioning of MAC or Clinique. Six years later, the calculus has reversed. ## How Did the Dr.Jart+ Thesis Unravel? Dr.Jart+ ran into the same headwinds that have battered most of Estée Lauder's portfolio since 2022: a slowdown in mainland China prestige beauty, persistent softness in Asian duty-free and travel retail, and rising competition from a new generation of indie K-beauty brands selling direct-to-consumer through Amazon, Olive Young, and TikTok Shop. The travel-retail channel was foundational to Dr.Jart+'s Estée Lauder–era growth, and its decline removed a structural pillar from the brand's revenue model. The divestment is also part of a much larger strategic reset under chief executive Stéphane de La Faverie, who assumed the role in January 2025 and unveiled a turnaround plan titled Beauty Reimagined. That plan calls for cutting between 5,800 and 7,000 positions globally, consolidating regional operations into four geographic clusters, and reorganizing the brand portfolio into category clusters, according to coverage in [WWD](https://wwd.com/beauty-industry-news/beauty-features/inside-estee-lauder-ceo-stephane-de-la-faveries-reset-prestige-beauty-giant-1237109135/){rel="nofollow noopener" target="_blank"}. Asked publicly about persistent divestment rumors earlier this year, de La Faverie said the company was reviewing whether each brand was "in the right position." The May 15 disclosure resolves that question for three of them. Notably, the company is no longer marketing the three brands as a single package. Too Faced and Smashbox are being offered together, and Dr.Jart+ is being shopped separately. Final bids are reportedly in, and sources cited by WWD expect the process to close within weeks. ## What the Sale Signals for Clinical-Positioned Skincare The reversal of the 2019 thesis is the more interesting story for skincare-focused readers. Dr.Jart+ was, for a period, the most visible argument for the idea that a dermatologist-led K-beauty brand could scale globally inside a Western prestige conglomerate. Its valuation in 2019 effectively priced that thesis at $1.7 billion. The 2026 sale of all three brands for an estimated low-nine-figure total suggests the conglomerate model now assigns a far lower premium to clinical K-beauty than it did before the China prestige slowdown and the rise of direct-to-consumer indie brands. For the broader category, the divestment is less an indictment of clinical skincare than a recalibration of where its value lives. Clinical positioning, ingredient transparency, and barrier-first formulation are now near-universal in prestige skincare, including in [conglomerate-owned brands](/trends/fragrance-allergens-skincare-eu-81-list-mechanism/) and emerging indies. The premium has migrated from the positioning itself to the ability to convert that positioning into a community, a sales channel, and a regulatory story. ## What Happens to Dr.Jart+ Next The buyer profile for Dr.Jart+ is likely to differ from the buyer profile for the color cosmetics package. A standalone K-beauty asset with strong U.S. distribution at Sephora and a recognized clinical line is a plausible target for a Korean strategic acquirer looking for a re-entry into Western prestige retail, for a private equity firm focused on beauty roll-ups, or for an Asian conglomerate seeking a global skincare platform. Sources cited by WWD have indicated that one party expressed interest in all three brands, while others have focused on the color brands or on Dr.Jart+ alone. Estée Lauder declined to comment publicly on the bidder pool. For consumers, the immediate product impact will be limited. Cicapair, Ceramidin, and the brand's other clinical lines will continue to ship through existing retail channels until a transaction closes and a new owner sets a strategy. The longer-term question is whether the brand's clinical-led identity survives a third ownership transition, or whether the next buyer reformulates the positioning to chase a different consumer segment.